drugset / Trial / NCT00323570
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma
RandomizedParallel-groupDouble-blindTreatment
Summary
This trial is conducted in the United States of America (USA). The purpose of this study is to evaluate the treatment of Recombinant Faction VIIa in Patients with Severe Bleeding Due to Trauma Please note that this trial and trial F7TRAUMA-1711 (NCT00184548) have been merged.
Timeline
- Start
- 2006-05
- Primary completion
- 2007-06
- Completion
- 2007-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | eptacog alfa (activated) | Protein / enzyme biologic | — | — |